NCT05935098

BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors

A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-A3055, Alone and in Combination With Tislelizumab in Patients With Selected Advanced or Metastatic Solid Tumors

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 99 (actual)
• Sponsor: BeiGene · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study aims to evaluate how safe and well-tolerated the treatment is, how the body processes it, how it works on the tumors, and whether it shows early signs of fighting cancer in people with certain advanced or metastatic solid tumors. Key details of the study include: * The study is expected to last about 36 months. * Participants will receive treatment until they either no longer benefit from the treatment, experience side effects that are too severe, or choose to stop participating.

Conditions

• Advanced Solid Tumor
• Metastatic Solid Tumor
• Solid Tumor

Interventions

Type	Name	Description
DRUG	BGB-A3055	Administered intravenously
DRUG	Tislelizumab	Administered intravenously
DRUG	Chemotherapy	Administered in accordance with relevant local guidelines and/or prescribing information.

Timeline

• Start date: 2023-08-21
• Primary completion: 2026-01-27
• Completion: 2026-01-27
• First posted: 2023-07-07
• Last updated: 2026-03-13

Locations

26 sites across 5 countries: United States, Australia, China, France, South Korea

Regulatory

• FDA-regulated drug study